Karyopharm Therapeutics (KPTI) Stock Forecast & Price Target

Compare

1,206 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KPTI Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Karyopharm

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KPTI Stock 12 Month Forecast

Average Price Target

$13.83

▲(90.23% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is $13.83 with a high forecast of $21.00 and a low forecast of $6.00. The average price target represents a 90.23% change from the last price of $7.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","7":"$7","12":"$12","17":"$17","22":"$22"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,7,12,17,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.75,6.923076923076923,8.096153846153847,9.26923076923077,10.442307692307693,11.615384615384617,12.788461538461538,13.961538461538462,15.134615384615385,16.307692307692307,17.480769230769234,18.653846153846153,19.826923076923077,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.75,6.371538461538462,6.993076923076924,7.614615384615385,8.236153846153847,8.857692307692307,9.47923076923077,10.100769230769231,10.722307692307693,11.343846153846155,11.965384615384616,12.586923076923078,13.208461538461538,{"y":13.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.75,5.769230769230769,5.788461538461538,5.8076923076923075,5.826923076923077,5.846153846153846,5.865384615384615,5.884615384615385,5.903846153846154,5.923076923076923,5.9423076923076925,5.961538461538462,5.980769230769231,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$21.00

Average Price Target$13.83

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Tenthoff

Piper Sandler

$12

Buy

65.06%

Upside

Reiterated

12/17/25

Piper Sandler Remains a Buy on Karyopharm Therapeutics (KPTI)

Robert Burns

H.C. Wainwright

$15

Buy

106.33%

Upside

Reiterated

11/04/25

Karyopharm Therapeutics (KPTI) Gets a Buy from H.C. Wainwright

Peter Lawson

Barclays

$10

Buy

37.55%

Upside

Reiterated

11/04/25

Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)

Brian Abrahams

RBC Capital

$30→$19

Buy

161.35%

Upside

Reiterated

11/03/25

Karyopharm price target lowered to $19 from $30 at RBC CapitalKaryopharm price target lowered to $19 from $30 at RBC Capital

Jonathan Chang

Leerink Partners

$8→$6

Hold

-17.47%

Downside

Reiterated

10/10/25

Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating

Colleen M. Kusy

Robert W. Baird

$25→$21

Buy

188.86%

Upside

Reiterated

10/09/25

Karyopharm price target lowered to $21 from $25 at BairdKaryopharm price target lowered to $21 from $25 at Baird

Christopher Raymond

Raymond James

$75

Buy

931.64%

Upside

Assigned

01/27/25

Piper Sandler Issues a Buy Rating on Karyopharm Therapeutics (KPTI)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Tenthoff

Piper Sandler

$12

Buy

65.06%

Upside

Reiterated

12/17/25

Piper Sandler Remains a Buy on Karyopharm Therapeutics (KPTI)

Robert Burns

H.C. Wainwright

$15

Buy

106.33%

Upside

Reiterated

11/04/25

Karyopharm Therapeutics (KPTI) Gets a Buy from H.C. Wainwright

Peter Lawson

Barclays

$10

Buy

37.55%

Upside

Reiterated

11/04/25

Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)

Brian Abrahams

RBC Capital

$30→$19

Buy

161.35%

Upside

Reiterated

11/03/25

Karyopharm price target lowered to $19 from $30 at RBC CapitalKaryopharm price target lowered to $19 from $30 at RBC Capital

Jonathan Chang

Leerink Partners

$8→$6

Hold

-17.47%

Downside

Reiterated

10/10/25

Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating

Colleen M. Kusy

Robert W. Baird

$25→$21

Buy

188.86%

Upside

Reiterated

10/09/25

Karyopharm price target lowered to $21 from $25 at BairdKaryopharm price target lowered to $21 from $25 at Baird

Christopher Raymond

Raymond James

$75

Buy

931.64%

Upside

Assigned

01/27/25

Piper Sandler Issues a Buy Rating on Karyopharm Therapeutics (KPTI)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Karyopharm Therapeutics

1 Month

xxx

Success Rate

9/33 ratings generated profit

Average Return

-5.27%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 27.27% of your transactions generating a profit, with an average return of -5.27% per trade.

3 Months

xxx

Success Rate

7/19 ratings generated profit

Average Return

-11.69%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of -11.69% per trade.

1 Year

Brian AbrahamsRBC Capital

Success Rate

7/33 ratings generated profit

Average Return

-31.72%

reiterated a buy rating 2 months ago

Copying Brian Abrahams's trades and holding each position for 1 Year would result in 21.21% of your transactions generating a profit, with an average return of -31.72% per trade.

2 Years

xxx

Success Rate

6/33 ratings generated profit

Average Return

-38.35%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -38.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KPTI Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KPTI has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. KPTI average Analyst price target in the past 3 months is 13.83.

Each month's total comprises the sum of three months' worth of ratings.

KPTI Financial Forecast

KPTI Earnings Forecast

Next quarter’s earnings estimate for KPTI is -$2.08 with a range of -$3.06 to -$1.00. The previous quarter’s EPS was -$3.82. KPTI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KPTI has Performed in-line its overall industry.

KPTI Sales Forecast

Next quarter’s sales forecast for KPTI is $35.84M with a range of $33.35M to $39.36M. The previous quarter’s sales results were $44.04M. KPTI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KPTI has Performed in-line its overall industry.

KPTI Stock Forecast FAQ

What is KPTI’s average 12-month price target, according to analysts?

Based on analyst ratings, Karyopharm Therapeutics’s 12-month average price target is 13.83.

What is KPTI’s upside potential, based on the analysts’ average price target?

Karyopharm Therapeutics has 90.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KPTI a Buy, Sell or Hold?

Karyopharm Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Karyopharm Therapeutics’s price target?

The average price target for Karyopharm Therapeutics is 13.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $6.00. The average price target represents 90.23% Increase from the current price of $7.27.

What do analysts say about Karyopharm Therapeutics?

Karyopharm Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of KPTI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Karyopharm Therapeutics (KPTI) Stock Forecast & Price Target

KPTI Analyst Ratings

KPTI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Karyopharm Therapeutics

KPTI Analyst Recommendation Trends

KPTI Financial Forecast

KPTI Earnings Forecast

KPTI Sales Forecast

KPTI Stock Forecast FAQ

Detailed List of Analyst Forecasts